Want to see IL:TEVA full AI Analyst Report?
TEVA Stock Chart & Stats
11030.00
-80.00(-0.84%)
At close: 4:00 PM EDT
11030.00
-80.00(-0.84%)
Day’s Range― - ―
52-Week Range6,082.00 - 11,530.00
Previous CloseN/A
Volume1.19M
Average Volume (3M)1.02M
Market Cap
₪127.72B
Enterprise Value154.00K
Total Cash (Recent Filing)₪3.63B
Total Debt (Recent Filing)₪16.76B
Price to Earnings (P/E)57.8
Beta0.57
Next Earnings
Nov 11, 2026EPS Estimate
208.3Next Dividend Ex-DateN/A
Dividend Yield1.67%
Share Statistics
EPS (TTM)0.63
Shares Outstanding1,165,296,100
10 Day Avg. Volume1,016,654
30 Day Avg. Volume1,018,591
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.58
Price to Sales (P/S)1.94
P/FCF Ratio14.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.97
Revenue Forecast (FY)₪50.22B
Bulls Say, Bears Say
Bulls Say
Innovative Portfolio GrowthRapid growth in innovative medicines is shifting Teva toward differentiated products with stronger economics. Rising portfolio contribution and raised AUSTEDO, AJOVY and UZEDY guidance can improve growth quality and reduce reliance on commoditized generics.
Strong Cash Generation And MarginsImproving free cash flow and gross margins indicate that Teva’s operational recovery is translating into cash, not only accounting earnings. Continued mix improvement and transformation savings could support sustained margin expansion and internal funding capacity.
Biosimilars Platform ExpansionThe expanding biosimilars portfolio creates a longer-duration growth platform alongside Teva’s generic and specialty businesses. Marketed products, pipeline depth and partnership-led expansion can strengthen scale, diversify revenue and support future launches.
Bears Say
Elevated LeverageAlthough leverage is improving, the debt burden remains a material constraint on financial flexibility. High net debt can limit acquisitions, shareholder returns and investment capacity, while leaving less resilience if generic pricing or earnings weaken.
Generic Revenue PressureThe loss of REVLIMID exposes Teva to the volatility of patent-driven generic revenue and difficult comparisons. Ongoing competition, fewer high-value launches and pricing pressure could keep the core business from delivering consistent growth.
Approval And Payer-access RiskTeva’s growth strategy depends on converting pipeline assets and specialty products into reimbursed commercial sales. Regulatory decisions, payer restrictions and post-IRA access changes could delay launches, reduce uptake or weaken the returns on development investment.
Teva News
TEVA FAQ
What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?
Teva Pharmaceutical Industries Limited lowest stock price was 6082.00 and its highest was 11530.00 in the past 12 months.
What is Teva Pharmaceutical Industries Limited’s market cap?
Teva Pharmaceutical Industries Limited’s market cap is ₪127.72B.
When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?
Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Nov 11, 2026 which is in 63 days.
How were Teva Pharmaceutical Industries Limited’s earnings last quarter?
Teva Pharmaceutical Industries Limited released its earnings results on Jul 29, 2026. The company reported 6.2 earnings per share for the quarter, missing the consensus estimate of 15.6 by -9.4.
Is Teva Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Overvalued.
Does Teva Pharmaceutical Industries Limited pay dividends?
Teva Pharmaceutical Industries Limited pays a Quarterly dividend of 8.5 which represents an annual dividend yield of 1.67%. See more information on Teva Pharmaceutical Industries Limited dividends here
What is Teva Pharmaceutical Industries Limited’s EPS estimate?
Teva Pharmaceutical Industries Limited’s EPS estimate is 208.3.
How many shares outstanding does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited has 1,165,296,100 shares outstanding.
What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?
Teva Pharmaceutical Industries Limited reported an EPS of 6.2 in its last earnings report, missing expectations of 15.6. Following the earnings report the stock price went up 10.172%.
Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in IL:TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products throughout North America, Europe, and other international regions. The company's diverse portfolio encompasses sterile preparations, hormonal therapies, high-potency drugs, and cytotoxic substances, supplied in a wide array of dosage forms such as tablets, capsules, injectable solutions, inhalants, oral liquids, transdermal patches, topical ointments, and creams. Furthermore, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). A significant portion of its research and product development is concentrated on the central nervous system, pain management, respiratory illnesses, and oncology. Leading products for the central nervous system include Copaxone, utilized for relapsing multiple sclerosis; AJOVY, an option for migraine prevention; and AUSTEDO, prescribed for tardive dyskinesia and chorea linked to Huntington's disease. Within the respiratory domain, addressing asthma and chronic obstructive pulmonary disease, Teva offers products like ProAir, QVAR, various Digihaler and RespiClick formulations, along with BRALTUS and CINQAIR/CINQAERO. Their oncology division features treatments such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company also collaborates with MedinCell on the creation and commercialization of multiple extended-release injectable products, including a risperidone suspension designed for individuals with schizophrenia. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
